A detailed history of Mariner, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Mariner, LLC holds 19,688 shares of BCRX stock, worth $139,391. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,688
Previous 24,449 19.47%
Holding current value
$139,391
Previous $219,000 31.96%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

SELL
$7.55 - $9.06 $35,945 - $43,134
-4,761 Reduced 19.47%
19,688 $149,000
Q2 2025

Aug 14, 2025

BUY
$6.41 - $11.19 $17,980 - $31,387
2,805 Added 12.96%
24,449 $219,000
Q1 2025

May 15, 2025

BUY
$7.06 - $9.39 $59,205 - $78,744
8,386 Added 63.25%
21,644 $162,000
Q4 2024

Feb 13, 2025

BUY
$7.03 - $8.43 $22,664 - $27,178
3,224 Added 32.13%
13,258 $99,000
Q3 2024

Nov 13, 2024

BUY
$6.41 - $8.69 $64,317 - $87,195
10,034 New
10,034 $76,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.32B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Mariner, LLC Portfolio

Follow Mariner, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.